Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Simultaneous bone marrow involvement by CLL/SLL and LEF1/cyclin D1-positive metastatic melanoma

Kirill A. Lyapichev, Fatima Z. Jelloul

Blood (2020) 136 (2): 258.

https://doi.org/10.1182/blood.2020006057

Published: 2020

Journal Articles

Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series

Karthik Gnanapandithan, MD MS, Prakash Kharel, MD, Alyssa Grimshaw, MSLIS, Smith Giri, MBBS

Blood (2019) 134 (Supplement_1): 3606.

https://doi.org/10.1182/blood-2019-132203

Published: 2019

Journal Articles

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]

Philip A. Thompson, MBBS, Michael J Keating, MBBS, Nitin Jain, MD, Alessandra Ferrajoli, MD, Tapan M. Kadia, MD, Prithviraj Bose, MD, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 358.

https://doi.org/10.1182/blood-2019-129230

Published: 2019

Journal Articles

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

Greta De Jong, Sophie E Levie, Remko Schotte, PhD, Wouter Pos, PhD, Daniel Go, Etsuko Yasuda, Madalina Cercel, Susan E van Hal-van Veen, Esmay Frankin, Anikó Szabó, MD, Julien Villaudy, PhD, Pauline M van Helden, PhD, Hans van Eenennaam, PhD, Hergen Spits, PhD, Anita W Rijneveld, MD PhD, Mette D Hazenberg, MD PhD

Blood (2019) 134 (Supplement_1): 4461.

https://doi.org/10.1182/blood-2019-127894

Published: 2019

Journal Articles

Immune-Tumor Interactions in Resistance to Cancer Immunotherapy

Kai W. Wucherpfennig, MD PhD

Blood (2019) 134 (Supplement_1): SCI-45.

https://doi.org/10.1182/blood-2019-121065

Published: 2019

Journal Articles

Cytokine Release Syndrome As a Rare Complication of Nivolumab: A Case Report

Alexander Slota, MD, Roomana Khan, MD, Akhil Rahman, MD, Eiran A Warner, MD

Blood (2019) 134 (Supplement_1): 5630.

https://doi.org/10.1182/blood-2019-127586

Published: 2019

Journal Articles

Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Neil L Berinstein, MD, Isabelle Bence-Bruckler, MD, Pierre Laneuville, MD FRCPC, Douglas A. Stewart, MD, Nicholas Allen Forward, MDMSc,FRCPC, Liam Smyth, MDFRCPath, Gail Klein, MSc, Nancy Pennell, BSc, Kim Roos, BA, BSc

Blood (2019) 134 (Supplement_1): 3236.

https://doi.org/10.1182/blood-2019-125963

Published: 2019

Journal Articles

Bleeding Risk of Low-Molecular Weight Heparin Vs Direct Oral Anticoagulant in Patients with Intracranial Tumors

R Sumner Abraham, IV, MD, Trish A Millard, MD, Surabhi Palkimas, PharmD, Nolan A Wages, PhD, Hillary S. Maitland, MD MS

Blood (2018) 132 (Supplement 1): 2524.

https://doi.org/10.1182/blood-2018-99-113949

Published: 2018

Journal Articles

Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis

Lucia Masarova, MD, Srdan Verstovsek, MD PhD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Prithviraj Bose, MD, Maro N. Ohanian, DO, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Romany Gergis, Gautam Borthakur, MD, Zeev E. Estrov, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Naval G. Daver, MD

Blood (2018) 132 (Supplement 1): 352.

https://doi.org/10.1182/blood-2018-99-120251

Published: 2018

Journal Articles

Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas

Hidong Kim, MD, Laura Harper, MD, Thomas M. Habermann, MD, Grzegorz S. Nowakowski, MD, Carrie A. Thompson, MD, Patrick Johnston, Thomas E. Witzig, MD, Cristine Allmer, BS, Matthew J. Maurer, MS, James R. Cerhan, MD PhD, Jason Young, MD, Gita Thanarajasingam, MD

Blood (2018) 132 (Supplement 1): 5401.

https://doi.org/10.1182/blood-2018-99-117711

Published: 2018

Journal Articles

Expansion and Characterization of Iovance Marrow Infiltrating Lymphocytes: A Potential Novel Therapeutic Strategy for the Treatment of Acute Myeloid Leukemia

Lavakumar Karyampudi, PhD, Ian Frank, Michelle Blaskovich, John C. Byrd, MD, Cecile Chartier, Meixiao Long, MD

Blood (2018) 132 (Supplement 1): 5683.

https://doi.org/10.1182/blood-2018-99-114825

Published: 2018

Journal Articles

Sex Differences in Visceral Fat Measured with Computed Tomography Helps Predict Progression Free Survival in Patients with Diffuse Large B-Cell Lymphoma

Stephanie Teja, MD, Marcus Watkins, PhD, Joseph Ippolito, MD PhD, Shama Jaswal, Vincent Mellnick, Neha Mehta-Shah, MD

Blood (2018) 132 (Supplement 1): 2974.

https://doi.org/10.1182/blood-2018-99-111572

Published: 2018

Journal Articles

Analysis of Outcome of Patients Treated with Anti PD-1/Pdl-1 Therapy According to the Degree of Lymphopenia

Sarbajit Mukherjee, MD, Michael Machiorlatti, Bilal Khalid, MD, Gabriel Souza Vidal, MD, Jennifer Holter Charkrabarty, MD, Mohamad A. Cherry, MDMS

Blood (2017) 130 (Supplement 1): 3594.

https://doi.org/10.1182/blood.V130.Suppl_1.3594.3594

Published: 2017

Journal Articles

Evaluating Pembrolizumab Interference with Monoclonal Protein Detection By Immunofixation and By MALDI-TOF Mass Spectrometry (MASS-FIX)

Taxiarchis Kourelis, MD, David L. Murray, MDPhD, Angela Dispenzieri, MD, Jody L. Frinack, B.S., Melea D. Hetrick, B.S., Maria Alice V. Willrich, PhD

Blood (2017) 130 (Supplement 1): 4428.

https://doi.org/10.1182/blood.V130.Suppl_1.4428.4428

Published: 2017

Journal Articles

Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma

Sharmilan Thanendrarajan, MD, Jerry Puryear, PharmD, Carolina D. Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Pankaj Mathur, MD, Meera Mohan, MD, Sandra Susanibar, MD, Jorge Jo Kamimoto, MD, Shadiqul Hoque, MD, Muthukumar Radhakrishnan, MD, Phil Farmer, Leo Rasche, MD, Niels Weinhold, PhD, Brian A Walker, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD

Blood (2017) 130 (Supplement 1): 1858.

https://doi.org/10.1182/blood.V130.Suppl_1.1858.1858

Published: 2017

Journal Articles

Impact of Treatment on IL-10, CTLA-4 and PD-L1 Gene Expression in Patients with Classical Hodgkin Lymphoma

Priscilla Brito Silva, MSc, Juliana Monte Real, PhD, Ludmila Rodrigues Pinto Ferreira, PhD, Gustavo Henrique Esteves, PhD, Joao Garibaldi Junior, MD, Adriana M. Damasco Penna, MD PhD, Fabio Nascimento Brito, MD, Egyla Cavalcante, MD, Otavio C. G. Baiocchi, MD PhD

Blood (2016) 128 (22): 5290.

https://doi.org/10.1182/blood.V128.22.5290.5290

Published: 2016

Journal Articles

BRAF V600E Targetable Mutation in Relapsed/Refractory Multiple Myeloma (R/R MM) Patients: A High Incidence in R/R MM Detected Using Cell Sorting Screening

Alina Danu, MD, Sophie Cotteret, PhD, Ludovic Lacroix, Véronique Saada, PharmD, Véronique Vergé, MD, Nathalie Auger, Julien Lazarovici, MD, Edith Carton, Jonathan Farhi, Khalil Saleh, MD, David Ghez, PhD MD, Claude Chahine, MD, Jean-Marie Michot, MD, Vincent Ribrag, MD

Blood (2016) 128 (22): 5638.

https://doi.org/10.1182/blood.V128.22.5638.5638

Published: 2016

Journal Articles

Innate Immune Sensing in Anti-Tumor Immunity and Cancer Immunotherapy

Thomas Gajewski, MD PhD

Blood (2016) 128 (22): SCI-27.

https://doi.org/10.1182/blood.V128.22.SCI-27.SCI-27

Published: 2016

Journal Articles

Novel Technologies to Detect Minimal Residual Disease

Todd E. Druley, MD PhD

Blood (2016) 128 (22): SCI-31.

https://doi.org/10.1182/blood.V128.22.SCI-31.SCI-31

Published: 2016

Journal Articles

The Long PD-1 Receptor Binding Kinetics of Nivolumab May Increase Efficacy of Subsequent Therapy in Relapsed and Refractory Multiple Myeloma Patients

Samuel A. Funt, MD, David B. Page, MD, Deepika Cattry, BSc, MSc, Nikoletta Lendvai, MD PhD, Hani Hassoun, MD, Ola Landgren, MD PhD, Ivan M. Borrello, MD, Alexander M. Lesokhin, MD

Blood (2015) 126 (23): 3057.

https://doi.org/10.1182/blood.V126.23.3057.3057

Published: 2015

NARROW

Simultaneous bone marrow involvement by CLL/SLL and LEF1/cyclin D1-positive metastatic melanoma

Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

Immune-Tumor Interactions in Resistance to Cancer Immunotherapy

Cytokine Release Syndrome As a Rare Complication of Nivolumab: A Case Report

Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Bleeding Risk of Low-Molecular Weight Heparin Vs Direct Oral Anticoagulant in Patients with Intracranial Tumors

Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis

Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas

Expansion and Characterization of Iovance Marrow Infiltrating Lymphocytes: A Potential Novel Therapeutic Strategy for the Treatment of Acute Myeloid Leukemia

Sex Differences in Visceral Fat Measured with Computed Tomography Helps Predict Progression Free Survival in Patients with Diffuse Large B-Cell Lymphoma

Analysis of Outcome of Patients Treated with Anti PD-1/Pdl-1 Therapy According to the Degree of Lymphopenia

Evaluating Pembrolizumab Interference with Monoclonal Protein Detection By Immunofixation and By MALDI-TOF Mass Spectrometry (MASS-FIX)

Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma

Impact of Treatment on IL-10, CTLA-4 and PD-L1 Gene Expression in Patients with Classical Hodgkin Lymphoma

BRAF V600E Targetable Mutation in Relapsed/Refractory Multiple Myeloma (R/R MM) Patients: A High Incidence in R/R MM Detected Using Cell Sorting Screening

Innate Immune Sensing in Anti-Tumor Immunity and Cancer Immunotherapy

Novel Technologies to Detect Minimal Residual Disease

The Long PD-1 Receptor Binding Kinetics of Nivolumab May Increase Efficacy of Subsequent Therapy in Relapsed and Refractory Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only